Home> Products> Inhibitors> 9-Hydroxyellipticine Hydrochloride-CAS 52238-35-4
price inquiry for CAS:52238-35-4, Product:9-Hydroxyellipticine Hydrochloride

9-Hydroxyellipticine Hydrochloride CAS: 52238-35-4

Category: Inhibitors
Product Name: 9-Hydroxyellipticine Hydrochloride
Cat No: I000124
CAS No: 52238-35-4
Molecular Formula: C17H14N2O
Molecular Weight: 262.31
SMILES: OC1=CC2=C(NC3=C2C(C)=C(C=NC=C4)C4=C3C)C=C1.[H]Cl
InChI: InChI=1S/C17H14N2O.ClH/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17;/h3-8,19-20H,1-2H3;1H
InChIKey: DLDKVFOKLGPVBT-UHFFFAOYSA-N
Solubility: Soluble in DMSO, not in water
CAS 52238-35-4,9-Hydroxyellipticine Hydrochloride
  • Description

9-Hydroxyellipticine Hydrochloride(cas 52238-35-4), also known as IGIG 929 and LS133324, is a potent cytotoxic and antitumor agent. Structurally, 9-hydroxyellipticine is a 9-hydroxy derivative of ellipticine. The hydroxy group in 9-hydroxyellipticines increases the apparent affinity for DNA, stabilisation of toposiomerase II-DNA cleavable complex, oxidation to reactive quinone-imine intermediates, phosphorylation of p53 suppressor proteins and cytotoxicity relative to the parent ellipticines.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References

1: Harding MM, Grummitt AR. 9-hydroxyellipticine and derivatives as chemotherapy agents. Mini Rev Med Chem. 2003 Mar;3(2):67-76. Review. PubMed PMID: 12570841.
2: Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89(1):21-8. PubMed PMID: 12083739.
3: Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. Anticancer Res. 2001 Jul-Aug;21(4A):2671-5. PubMed PMID: 11724337.
4: Mizumoto K, Sato N, Kusumoto M, Niiyama H, Maehara N, Nishio S, Li Z, Ogawa T, Tanaka M. Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. Cancer Lett. 2000 Feb 28;149(1-2):85-94. PubMed PMID: 10737712.
5: Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors. Cancer Res. 1999 Oct 1;59(19):4927-36. PubMed PMID: 10519406.
6: Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 1999 Jul-Aug;19(4B):3099-108. PubMed PMID: 10652599.
7: Sato N, Mizumoto K, Kusumoto M, Niiyama H, Maehara N, Ogawa T, Tanaka M. 9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells. FEBS Lett. 1998 Dec 18;441(2):318-21. PubMed PMID: 9883907.


price inquiry for CAS:52238-35-4, Product:9-Hydroxyellipticine Hydrochloride